WebApr 14, 2024 · Autophagy Influences Hypoxia, Chemoresistance, and Stem-like Phenotype in Breast Cancer It is known that cancer stem cells are a significant contributor to the development of chemoresistance in breast cancer [ 88, 89, 90, 91 ]. Autophagy enables the survival of CSCs under hypoxia in the tumor microenvironment [ 92 ]. WebApr 14, 2024 · Hypoxia also upregulates the expression of PD-1 ligand 1 (PD-L1) on MDSCs, macrophages, dendritic cells, ... Guo Q et al (2024) Hypoxia exposure induced cisplatin resistance partially via activating p53 and hypoxia inducible factor-1α in non-small cell lung cancer A549 cells. Oncol Lett 16:801–808.
Comparative study of the PD-L1 expression and CD8+ tumor …
WebCisplatin may also cause upregulation of tumor cell PD-L1, which may in part explain the additive antitumor activity of cisplatin and PD-L1/PD-1 blockade. This information will help in interpreting results of ongoing clinical trials combining these agents, and for comparison of potential future therapeutic combinations for the treatment of head ... WebMay 1, 2024 · Since PD-L1 expression protects tumor cells from pro-apoptotic drugs, we hypothesized that the PD-1/PD-L1 axis might contribute to the acquisition of resistance … simpletimer.h library download arduino
STING agonist therapy in combination with PD-1 immune ... - Nature
WebNov 4, 2024 · These 13 genes identify a variety of cisplatin-resistance mechanisms including increased transport and detoxification of cisplatin, and mis-regulation of the epithelial to mesenchymal transition. Conclusions We identified gene signatures in resistant TNBC subtypes indicative of mechanisms of cisplatin. WebNevertheless, the role of PD-L1 in chemoresistance development is not fully understood. In the current study, we aim to clarify the interaction of miR-519d-3p and PD-L1 in the development of cisplatin resistance. Immunohistochemistry, quantitative reverse-transcription polymerase reaction, and Western blot were used to evaluate PD-L1 … WebPatients were randomized (1:1:1) to receive one of the following treatments: pembrolizumab as a single agent; pembrolizumab, carboplatin or cisplatin, and FU; or cetuximab, carboplatin or ... simpletimer.h github